Gastroenteropancreatic Neuroendocrine Tumor Clinical Trials in Clichy
3 recruitingClichy, France
Showing 1–3 of 3 trials
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals240 enrolled65 locationsNCT06784752
Recruiting
Phase 3
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Neuroendocrine TumorsGep NetCarcinoid Tumor+4 more
RayzeBio, Inc.338 enrolled54 locationsNCT05477576
Recruiting
Not Applicable
Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
RadiotherapyGastroenteropancreatic Neuroendocrine Tumor
Assistance Publique - Hôpitaux de Paris80 enrolled5 locationsNCT06256705